Amgen stock ends the day 1.95 percent higher at the close

At the close on September 21, 2026, Amgen stock finished 1.95 percent higher on the Nasdaq, outpacing the Dow Jones Industrial Average’s gain. The move came as investors focused on the biotech sector and Amgen’s obesity-drug pipeline, with the next session on September 22, 2026.

Amgen stock closed higher on the Nasdaq on September 21, 2026, gaining 1.95 percent versus the prior close as investors bought into the large-cap biotech name. Compared with the Dow Jones Industrial Average, which rose 0.71 percent the same day, the stock clearly outperformed the broader blue-chip benchmark. Sector attention around obesity and weight-loss treatments kept the company in focus after fresh commentary on its pipeline.

September 21, 2026 in numbers

Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) ended the regular session at USD 393.16 on the Nasdaq on September 21, 2026, adding 1.95 percent from a prior close of USD 385.65 per Investing.com data.Investing.com reported that Amgen rose 7.51 points to finish at USD 393.16 as the Dow Jones Industrial Average advanced 0.71 percent, underscoring the stock’s relative strength. A separate quote overview showed the prior close at USD 385.65, confirming the session’s positive bias.MarketScreener

In the broader healthcare context, Amgen remained part of the market’s focus on obesity drugs. Reuters noted that the company is conducting six late-stage trials of its experimental weight-loss drug MariTide across obesity and related conditions, contributing to sustained investor interest in large-cap obesity treatment developers. Against this backdrop, Amgen’s advance contrasted with volatility in other weight-loss names, while the Dow’s smaller gain highlighted the stock-specific bid.

After the bell and next session

After the close on September 21, 2026, extended trading in Amgen on electronic venues continued, with one data overview indicating a modestly softer after-hours quote versus the regular-session finish, though the main reference for investors remains the official Nasdaq close.MEXC Looking ahead, the next U.S. trading day is September 22, 2026, when Amgen stock will trade again on the Nasdaq against the backdrop of ongoing news flow around obesity-drug developers and broader biotech sentiment.